The Evolution of GLP-1: A Symbol of New Bio-Innovation Paradigms
Existing Practices Make Ecosystem Advancement Difficult

[The Editors' Verdict] Bio Sovereignty Cannot Be Secured Through Individual Survival Strategies View original image

Global investment and research by the biotech industry and academia into glucagon-like peptide-1 (GLP-1) amount to a challenge that could redraw the map of biotechnology entirely. Although GLP-1 is now widely known as the basis for anti-obesity drugs such as Wegovy and Mounjaro, the substance is in fact evolving toward a goal of treating dementia by traveling through the bloodstream, crossing the blood-brain barrier (BBB), and calming chronic inflammation in the brain's neural networks. The success of anti-obesity drugs, driven by GLP-1's ability to control the instinct of hunger, could therefore be seen as a major success in an "indirect clinical trial" that has offered advance proof of the potential to control brain function through metabolic regulation and, ultimately, conquer dementia.


Global pharmaceutical giants have a near-monopoly on key GLP-1-related pipelines. It is not far-fetched to imagine them dominating the development and commercialization of new GLP-1-based dementia drugs, then launching an offensive in markets around the world. In some circumstances, this could even threaten national health sovereignty. Consumers may be forced to shoulder exorbitant drug prices in full, or governments may have no choice but to pour public funds into a bottomless pit. The pharmaceutical industry is particularly difficult to escape once it becomes dependent on established interests. South Korea, which has entered a super-aged society, may have to bear an even greater cost.


Global competition over GLP-1 is emblematic of a new paradigm for biotech innovation: a single candidate drug expands into multiple indications, and one platform can create a market worth tens to hundreds of trillions of won all at once. From this perspective, the prevailing view is that South Korea's response remains complacent and fragmented. The problem is not limited to traditional industry practices in which major pharmaceutical companies follow in the footsteps of global pharma giants, focus on investing in formulation changes for treatments that are already nearing completion, wait for patents to expire, and concentrate on producing generics to secure profitability.



The ecosystem is weakened by a structure in which promising biotech companies, each fighting for survival, must struggle to secure funding by pinning their hopes on the initial public offering (IPO) market. Basic research, clinical trials, and regulatory approval have long been siloed across government ministries and driven by conflicting interests. That is why it is essential to create a tech bloc that brings together the discovery of drug candidates, development of delivery platforms, capital flows, and rationalization of regulations as a single task. The National Bio Innovation Committee, which aims to serve as a pan-government policy control tower, must do precisely this. Strategies that simply specify how much funding or budget will be allocated to each field are not enough to prepare for the era of a major biotech transformation. It must break free from the bureaucratic inertia of focusing on numbers and become a hands-on command center.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing